atogepant

Atogepant is a prescription medication used for the prevention of episodic migraine in adults. It is a small-molecule antagonist of the calcitonin gene-related peptide (CGRP) receptor, and it belongs to the gepant class of migraine therapies. The drug is marketed under the brand name Qulipta and was developed by AbbVie.

Mechanism of action: Atogepant binds selectively to CGRP receptors, blocking CGRP signaling. By inhibiting this pathway, it aims to reduce the frequency and severity of migraine attacks over time.

Administration and dosing: Atogepant is taken orally on a daily basis. Dosing is adjusted according to regulatory labeling and clinical response, rather than on an as-needed basis like some acute treatments.

Clinical use: It is indicated for the prevention of episodic migraine in adults and is not intended for acute treatment of migraine attacks. It may be considered for patients who experience frequent migraines or who have not achieved adequate relief with other preventive strategies.

Regulatory status and development: The U.S. Food and Drug Administration approved atogepant in 2021 for migraine prevention. It is part of a broader class of CGRP-targeted therapies used for preventive purposes.

Safety and adverse effects: Common adverse events reported in trials include nausea, constipation, and fatigue; most events are mild to moderate. As with other oral therapies targeting CGRP signaling, clinicians may monitor liver function and consider potential drug interactions, especially in patients with underlying hepatic disease or on concomitant medications. Overall, atogepant provides a non–monoclonal antibody option for adult migraine prevention.